Market Place
Sourcing Support
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre
19 Apr 2023 //
PR NEWSWIRE
Incyte Announces Japanese Approval of Pemazyre for the Treatment of MLNs
27 Mar 2023 //
BUSINESSWIRE
New treatment for rare cancer cholangiocarcinoma approved in Australia
15 Sep 2022 //
PRNEWSWIRE
FDA approves Incyte’s Pemazyre for treating myeloid/lymphoid neoplasms
29 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
Innovent Nabs Approval of Pemazyre by NMPA for Cholangiocarcinoma
06 Apr 2022 //
PRNEWSWIRE
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
31 Jan 2022 //
GLOBENEWSWIRE
Innovent Announces Approval of Pemazyre in Hong Kong Market
24 Jan 2022 //
PRNEWSWIRE
Incyte Announces Health Canada Conditional Approval of Pemazyre (pemigatinib)
17 Sep 2021 //
BIOSPACE
Innovent Announces NMPA Acceptance of New Drug Application for Pemigatinib
08 Jul 2021 //
PR NEWSWIRE
Incyte Announces Positive CHMP Opinion for Pemigatinib for the of Adults
29 Jan 2021 //
BUSINESSWIRE
Incyte Announces Health Canada Acceptance of the New Drug Sub for Pemigatinib
26 Oct 2020 //
NEWSWIRE
FDA OKs Incyte’s Pemazyre as first targeted drug for cholangiocarcinoma
21 Apr 2020 //
PMLIVE
Innovent Biologics Announces FDA Approval of Pemazyre™ (Pemigatinib)
20 Apr 2020 //
PRNASIA
Foundation Medicine Receives FDA Approval for FoundationOne®CDx
17 Apr 2020 //
BUSINESSWIRE
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib
02 Dec 2019 //
PR NEWSWIRE
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib
01 Dec 2019 //
PR NEWSWIRE
Innovent Biologics Proclaims Positive Result from Phase II Trial of Pemigatinib
21 Oct 2019 //
BIOSPACE
Innovent`s Announces +ve Result from the Incyte-sponsored PhII Pemigatinib
21 Oct 2019 //
BIOSPACE
Innovent, Incyte Licensing Agreement for 3 Clinical-stage Candidates in CN
21 Dec 2018 //
PR NEWSWIRE
Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor
10 Oct 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.